Related Experiment Video
Updated: Apr 15, 2026

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
Ocular inflammation associated with antivascular endothelial growth factor treatment
Howard F Fine1, Greg D Despotidis, Jonathan L Prenner
1Department of Ophthalmology, Rutgers Robert Wood Johnson Medical School, 10 Plum Street Suite 600, New Brunswick NJ 08901, USA.
Purpose Of Review:
To describe the diagnosis and management of intraocular inflammation following antivascular endothelial growth factor (VEGF) injections.
Recent Findings:
Inflammation following intravitreal anti-VEGF injections can cause a dramatic reduction in acuity. Differentiating factors from truly infectious endophthalmitis include a lack of pain, redness, or hypopyon, although none of these factors is diagnostic. A high suspicion of infectious endophthalmitis should trigger a prompt vitreous tap and injection of intravitreal antibiotics. Conversely, if noninfectious endophthalmitis is suspected, close observation with frequent topical steroids is warranted.
Summary:
Most eyes with noninfectious endophthalmitis following anti-VEGF injection recover within 1 month to baseline acuity with topical corticosteroid treatment. Mechanisms hypothesized to explain postinjection inflammation include patient-specific, delivery-specific, and medication-specific factors.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview

